New Guidelines for the Management of Patients with MI

Jennifer A. Ng, PharmD; Bao Q. Nguyen, PharmD; and Mohammad J. Tafreshi, PharmD, BCPS
Published Online: Monday, November 1, 2004

Statistics indicate that in 2001 there were ~1.7 million hospital discharges for acute coronary syndromes (ACS). According to the National Registry of Myocardial Infarction 4, it is estimated that ~30% of the ACS patients have ST-elevation myocardial infarction (STEMI). This percentage translates to ~500,000 STEMI events per year in the United States.1,2

New Guidelines

Recently, the American Heart Association (AHA), in partnership with the American College of Cardiology (ACC), published a new set of guidelines for the management of patients with STEMI.3 The focus of this article is on medications used in the management of STEMI patients.

For ease of comparison, a Table is provided that reviews and compares only the changes between the old (1999) and the new (2004) guidelines. Readers are encouraged to refer to the actual guidelines for a comprehensive review of each section.

Recommendation Classifications and Levels of Evidence

The customary ACC/AHA classifications (I, 7 IIa, IIb, and III) and levels of evidence (A, B, and C) are used in these guidelines:

  • Class I: Conditions for which there is evidence or general agreement that a given procedure or treatment is useful and effective
  • Class II: Conditions for which there is conflicting evidence or a divergence of opinion about the usefulness/efficacy of a procedure or treatment
  • Class IIa: Weight of evidence/opinion in favor of usefulness/ efficacy
  • Class IIb: Usefulness/efficacy less well established by evidence/opinion
  • Class III: Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful/effective and in some cases may be harmful
  • Level of Evidence A: Data derived from multiple population risk strata
  • Level of Evidence B: Data derived from limited population risk strata
  • Level of Evidence C: Data derived from very limited risk strata




For a list of references, send a stamped, self-addressed envelope to: References Department, Attn. A. Stahl, Pharmacy Times, 241 Forsgate Drive, Jamesburg, NJ 08831; or send an e-mail request to:

Dr. Ng is an instructor of pharmacy practice and a cardiology pharmacy practice resident, Midwestern University, College of Pharmacy-Glendale. Dr. Nguyen is a pharmacist with Banner Thunderbird Medical Center. Dr. Tafreshi is an associate professor of pharmacy and medicine and director of the cardiology pharmacy practice residency, Midwestern University, College of Pharmacy-Glendale.

Latest Articles
Having trouble getting your hands on FluMist?
Novartis is paying $390 million to settle charges that it paid kickbacks to pharmacies to encourage drug sales.
Anxiety sensitivity has been linked to more debilitating asthma symptoms and greater functional limitations.
Nasal corticosteroid sprays do not seem to be viable treatments for the common cold.
Latest Issues